BACKGROUND: Recent reports indicate that prostate cancers (CaP) frequently over-express the potential oncogenes, ERG or ETV1. Many cases have chromosomal rearrangements leading to the fusion of the 5' end of the androgen-regulated serine protease TMPRSS2 (21q22.2) to the 3' end of either ERG (21q22.3) or ETV1 (7p21.3). The consequence of these rearrangements is aberrant androgen receptor-driven expression of the potential oncogenes, ETV1 or ERG. AIM: To determine the frequency of rearrangements involving TMPRSS2, ERG, or ETV1 genes in CaP of varying Gleason grades through fluorescence in situ hybridisation (FISH) on CaP tissue microarrays (TMAs). METHODS: Two independent assays, a TMPRSS2 break-apart assay and a three-colour gene fusion FISH assay were applied to TMAs. FISH positive cases were confirmed by reverse transcriptase (RT) PCR and DNA sequence analysis. RESULTS: A total of 106/196 (54.1%) cases were analysed by FISH. None of the five benign prostatic hyperplasia cases analysed exhibited these gene rearrangements. TMPRSS2:ERG fusion was found more frequently in moderate to poorly differentiated tumours (35/86, 40.7%) than in well differentiated tumours (1/15, 6.7%, p = 0.017). TMPRSS2:ETV1 gene fusions were not detected in any of the cases tested. TMPRSS2:ERG fusion product was verified by RT-PCR followed by DNA sequencing in 7/7 randomly selected positive cases analysed. CONCLUSION: This study indicates that TMPRSS2:ERG gene rearrangements in CaP may be used as a diagnostic tool to identify prognostically relevant sub-classifications of these cancers.
BACKGROUND: Recent reports indicate that prostate cancers (CaP) frequently over-express the potential oncogenes, ERG or ETV1. Many cases have chromosomal rearrangements leading to the fusion of the 5' end of the androgen-regulated serine protease TMPRSS2 (21q22.2) to the 3' end of either ERG (21q22.3) or ETV1 (7p21.3). The consequence of these rearrangements is aberrant androgen receptor-driven expression of the potential oncogenes, ETV1 or ERG. AIM: To determine the frequency of rearrangements involving TMPRSS2, ERG, or ETV1 genes in CaP of varying Gleason grades through fluorescence in situ hybridisation (FISH) on CaP tissue microarrays (TMAs). METHODS: Two independent assays, a TMPRSS2 break-apart assay and a three-colour gene fusion FISH assay were applied to TMAs. FISH positive cases were confirmed by reverse transcriptase (RT) PCR and DNA sequence analysis. RESULTS: A total of 106/196 (54.1%) cases were analysed by FISH. None of the five benign prostatic hyperplasia cases analysed exhibited these gene rearrangements. TMPRSS2:ERG fusion was found more frequently in moderate to poorly differentiated tumours (35/86, 40.7%) than in well differentiated tumours (1/15, 6.7%, p = 0.017). TMPRSS2:ETV1 gene fusions were not detected in any of the cases tested. TMPRSS2:ERG fusion product was verified by RT-PCR followed by DNA sequencing in 7/7 randomly selected positive cases analysed. CONCLUSION: This study indicates that TMPRSS2:ERG gene rearrangements in CaP may be used as a diagnostic tool to identify prognostically relevant sub-classifications of these cancers.
Authors: Karin G Hermans; Ronald van Marion; Herman van Dekken; Guido Jenster; Wytske M van Weerden; Jan Trapman Journal: Cancer Res Date: 2006-11-15 Impact factor: 12.701
Authors: T Mastrangelo; P Modena; S Tornielli; F Bullrich; M A Testi; A Mezzelani; P Radice; A Azzarelli; S Pilotti; C M Croce; M A Pierotti; G Sozzi Journal: Oncogene Date: 2000-08-03 Impact factor: 9.867
Authors: Kristiina Iljin; Maija Wolf; Henrik Edgren; Santosh Gupta; Sami Kilpinen; Rolf I Skotheim; Mari Peltola; Frank Smit; Gerald Verhaegh; Jack Schalken; Matthias Nees; Olli Kallioniemi Journal: Cancer Res Date: 2006-11-01 Impact factor: 12.701
Authors: Nikita Makretsov; May He; Malcolm Hayes; Stephen Chia; Doug E Horsman; Poul H B Sorensen; David G Huntsman Journal: Genes Chromosomes Cancer Date: 2004-06 Impact factor: 5.006
Authors: Bo Han; Rohit Mehra; Saravana M Dhanasekaran; Jindan Yu; Anjana Menon; Robert J Lonigro; Xiaosong Wang; Yusong Gong; Lei Wang; Sunita Shankar; Bharathi Laxman; Rajal B Shah; Sooryanarayana Varambally; Nallasivam Palanisamy; Scott A Tomlins; Chandan Kumar-Sinha; Arul M Chinnaiyan Journal: Cancer Res Date: 2008-09-15 Impact factor: 12.701
Authors: Juan-Miguel Mosquera; Sven Perner; Elizabeth M Genega; Martin Sanda; Matthias D Hofer; Kirsten D Mertz; Pamela L Paris; Jeff Simko; Tarek A Bismar; Gustavo Ayala; Rajal B Shah; Massimo Loda; Mark A Rubin Journal: Clin Cancer Res Date: 2008-06-01 Impact factor: 12.531
Authors: Liyan Xue; Xueying Mao; Guoping Ren; Elzbieta Stankiewicz; Sakunthala C Kudahetti; Dongmei Lin; Luis Beltran; Daniel M Berney; Yong-Jie Lu Journal: Am J Cancer Res Date: 2012-11-20 Impact factor: 6.166
Authors: Scott A Tomlins; Bharathi Laxman; Sooryanarayana Varambally; Xuhong Cao; Jindan Yu; Beth E Helgeson; Qi Cao; John R Prensner; Mark A Rubin; Rajal B Shah; Rohit Mehra; Arul M Chinnaiyan Journal: Neoplasia Date: 2008-02 Impact factor: 5.715